Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential

References

• ShanklandKRArmitageJOHancockBWNon-Hodgkin lymphomaLancet2012380984484885722835603
   PubMed Web of Science ®Google Scholar
• SEERSEER Stat Fact Sheets: Non-Hodgkin LymphomaBethesda, MDNational Cancer Institute2012
   Google Scholar
• GopalAKKahlBSde VosSPI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphomaN Engl J Med2014370111008101824450858
   PubMed Web of Science ®Google Scholar
• MortonLMWangSSDevesaSSHartgePWeisenburgerDDLinetMSLymphoma incidence patterns by WHO subtype in the United States, 1992–2001Blood2006107126527616150940
   PubMed Web of Science ®Google Scholar
• LunningMAVoseJMManagement of indolent lymphoma: where are we now and where are we goingBlood Rev201226627928823063143
   PubMed Web of Science ®Google Scholar
• JaffeESRelationship of classification to biologic behavior of non-Hodgkin’s lymphomasSemin Oncol1986134 suppl 5392879356
   PubMed Web of Science ®Google Scholar
• HowladerNNooneAMKrapchoMwebpage on the InternetSEER Cancer Statistics Review197520122015 Available from: http://seer.cancer.gov/csr/1975_2012/Accessed October 6, 2015
   Google Scholar
• HorningSJNatural history of and therapy for the indolent non-Hodgkin’s lymphomasSemin Oncol1993205 suppl 575888211209
   PubMed Web of Science ®Google Scholar
• TrebouetAMarchandTLemalRLymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSAAnn Oncol201324102612261823970017
   PubMed Web of Science ®Google Scholar
• Solal-CelignyPRoyPColombatPFollicular lymphoma international prognostic indexBlood200410451258126515126323
   PubMed Web of Science ®Google Scholar
• CasuloCByrtekMDawsonKLEarly relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare StudyJ Clin Oncol201533232516252226124482
   PubMed Web of Science ®Google Scholar
• PastoreAJurinovicVKridelRIntegration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryLancet Oncol20151691111112226256760
   PubMed Web of Science ®Google Scholar
• SmithAHowellDPatmoreRJackARomanEIncidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research NetworkBr J Cancer2011105111684169222045184
   PubMed Web of Science ®Google Scholar
• NabhanCSmithSMHelenowskiIAnalysis of very elderly (≥80 years) non-Hodgkin lymphoma: impact of functional status and co-morbidities on outcomeBr J Haematol2012156219620422084970
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [webpage on the Internet]NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas (version 1.2015)2015 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#siteAccessed October 6, 2015
   Google Scholar
• HainsworthJDRituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma: interim follow-up of a multicenter phase II trialSemin Oncol2002291 suppl 2252911842385
   PubMed Web of Science ®Google Scholar
• SchulzHBohliusJFTrelleSImmunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysisJ Natl Cancer Inst200799970671417470738
   PubMed Web of Science ®Google Scholar
• HiddemannWKnebaMDreylingMFrontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2005106123725373216123223
   PubMed Web of Science ®Google Scholar
• CzuczmanMSWeaverRAlkuzwenyBBerlfeinJGrillo-LopezAJProlonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-upJ Clin Oncol200422234711471615483015
   PubMed Web of Science ®Google Scholar
• MarcusRImrieKBelchACVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood200510541417142315494430
   PubMed Web of Science ®Google Scholar
• MarcusRImrieKSolal-CelignyPPhase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphomaJ Clin Oncol200826284579458618662969
   PubMed Web of Science ®Google Scholar
• RummelMJNiederleNMaschmeyerGBendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialLancet201338198731203121023433739
   PubMed Web of Science ®Google Scholar
• American Cancer Society [webpage on the Internet]Cancer Facts & Figures 2015 Available from: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdfAccessed March 31, 2015
   Google Scholar
• CasuloCBurackWRFriedbergJWTransformed follicular non-Hodgkin lymphomaBlood20151251404725499449
   PubMed Web of Science ®Google Scholar
• PressOWUngerJMRimszaLMPhase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016J Clin Oncol201331331432023233710
   PubMed Web of Science ®Google Scholar
• ChaoMPTreatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapiesCancer Manage Res20135251269
   PubMedGoogle Scholar
• NabhanCByrtekMRaiADisease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United StatesBr J Haematol20151701859525851937
   PubMed Web of Science ®Google Scholar
• HiddemannWChesonBDHow we manage follicular lymphomaLeukemia20142871388139524577532
   PubMed Web of Science ®Google Scholar
• VanhaesebroeckBWelhamMJKotaniKP110delta, a novel phosphoinositide 3-kinase in leukocytesProc Natl Acad Sci U S A1997949433043359113989
   PubMed Web of Science ®Google Scholar
• VanhaesebroeckBGuillermet-GuibertJGrauperaMBilangesBThe emerging mechanisms of isoform-specific PI3K signallingNat Rev Mol Cell Biol201011532934120379207
   PubMed Web of Science ®Google Scholar
• PaulsSDLafargeSTLandegoIZhangTMarshallAJThe phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functionsFront Immunol2012322422908014
   PubMed Web of Science ®Google Scholar
• ForcelloNSaraiyaNIdelalisib: the first-in-class phosphatidylinositol 3-kinase inhibitor for relapsed CLL, SLL, and indolent NHLJ Adv Pract Oncol2014545545926328219
   PubMedGoogle Scholar
• SomozaJRKoditekDVillasenorAGStructural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase deltaJ Biol Chem2015290138439844625631052
   PubMed Web of Science ®Google Scholar
• LannuttiBJMeadowsSAHermanSECAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viabilityBlood2011117259159420959606
   PubMed Web of Science ®Google Scholar
• ZYDELIG® (idelalisib tablets) [full prescribing information]Foster City, CAGilead Sciences, Inc2014
   Google Scholar
• European Medicines Agency [webpage on the Internet]Idelalisib. Summary of Product Characteristics2014 Available from: https://www.medicines.org.uk/emc/medicine/29202Accessed October 6, 2015
   Google Scholar
• FlinnIWKahlBSLeonardJPIdelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphomaBlood2014123223406341324615776
   PubMed Web of Science ®Google Scholar
• de VosSWagner-JohnstonNDCoutreSEDurable responses following treatment with the PI3K-delta inhibitor idelalisib in combination with rituximab, bendamustine, or both, in recurrent indolent non-Hodgkin lymphoma: phase I/II resultsBlood201412421 abstract3063
   Web of Science ®Google Scholar
• Wagner-JohnstonNDGopalAKKahlBSPatient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL)J Clin Oncol201432e19554
   Web of Science ®Google Scholar
• SmithNXenakisABeckermanRChhatwalJGregorySABriggsAA decision-analytic model of idelalisib in relapsed or refractory patients with indolent non-Hodgkin lymphomaJ Clin Oncol201432e17655
   Web of Science ®Google Scholar
• SallesGSchusterSde VosSIdelalisib efficacy and safety in follicular lymphoma patients from a phase 2 studyPaper presented at: 2015 American Society of Clinical Oncology Annual MeetingMay 28–June 3, 2015Chicago, IL
   Google Scholar
• BarrientosJGhiaPPagelJOutcomes of anticoagulant or anti-platelet use in patients with chronic lymphocytic leukemia or indolent non-hodgkin lymphoma in idelalisib trialsPaper presented at: ASCO Annual MeetingMay 29–June 2, 2015Chicago, IL
   Google Scholar
• CoutreSEBarrientosJCBrownJRManagement of adverse events associated with idelalisib treatment – expert panel opinionLeuk Lymphoma201556120
   Web of Science ®Google Scholar
• LampsonBLMatosTKimHTIdelalisib given front-line for the treatment of chronic lymphocytic leukemia results in frequent and severe immune-mediated toxicitiesBlood201512623497
   Web of Science ®Google Scholar
• O’BrienSMLamannaNKippsTJA phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemiaBlood2015126252686269426472751
   PubMed Web of Science ®Google Scholar
• Imbruvica® (ibrutinib capsules) [full prescribing information]Horsham, PAJanssen Biotech, Inc2015
   Google Scholar
• FlinnIOkiYPatelMA phase 1 evaluation of duvelisib (IPI-145), a PI3K-δ,γ inhibitor, in patients with relapsed/refractory iNHLBlood201412421abstr802
   Web of Science ®Google Scholar
• DreylingMCunninghamDBouabdallahKPhase 2A study of copanlisib, a novel PI3K inhibitor, in patients with indolent lymphomaBlood201412421abstract1701
   Google Scholar
• BarrPMSaylorsGBForbes SpurgeonSEPhase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)J Clin Oncol2014325s abstract7059
   Google Scholar
• SmithSMPitcherBJungS-HUnexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202Blood2014124213091
   Web of Science ®Google Scholar
• CheahCYNastoupilLJNeelapuSSForbesSGOkiYFowlerNHLenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphomaBlood2015125213357335925999447
   PubMed Web of Science ®Google Scholar
• ZelenetzADRobakTCoiffierBIdelalisib plus bendamustine and rituximab(BR)is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double-blind placebo-controlled studyBlood201512623 abstract LBA-5
   Web of Science ®Google Scholar